Altimmune posts smaller-than-expected Q2 net loss per share

Altimmune

12/08/2026 12:43

Aug 12 (Reuters) - 
Overview
US biopharmaceutical firm's Q2 net loss per share beat analyst expectations
Company reported no revenue for Q2 2026
R&D expenses rose yr/yr due to ongoing ALD and MASH trials

Outlook
Company plans to request End-of-Phase 2 meeting with FDA for AUD program


Result Drivers
HIGHER R&D SPENDING - Co said increased R&D expenses were driven by ongoing ALD trial and startup costs for PERFORMA Phase 3 MASH trial, partially offset by lower costs after completing IMPACT Phase 2b trial
HIGHER G&A COSTS - Co attributed increased general and administrative expenses to higher professional services and compensation costs




Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
Beat
$0.12
$0.14 (10 Analysts)

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Altimmune Inc is $19.00, about 533.3% above its August 11 closing price of $3.00

Reuters Recommended Reads
Aug 11 - Sagimet Biosciences Q2 net loss widens on higher R&D costs
Aug 11 - Zura Bio Q2 net loss widens as R&D expenses rise
Aug 11 - LB Pharmaceuticals Q2 net loss widens on higher R&D costs



Press Release s3://eap-prd-eu-west-1-source-content/eap_feed_proxy/ucdp/news_glbnwr/2026-08-12/493ebfad-19ad-484a-ae4a-c4832e9b6206.json
 (Reporting by Rupali Chaudhary)
 ((Rupali.Chaudhary@thomsonreuters.com;))